Oxford Biomedica, a global leader in cell and gene therapy, welcomes Lucinda (Lucy) Crabtree, Ph.D., as the new Chief Financial Officer (CFO). Lucy will also serve as a member of the company’s board. Her appointment, initially announced in July, takes effect today.
Crabtree’s Experience
Before joining Oxford Biomedica, Lucy was CFO at MorphoSys AG, where she successfully led the company’s finance team through the acquisition by Novartis. She also held key leadership roles at Autolus Therapeutics, guiding the biopharmaceutical firm through its Nasdaq listing. With a solid background in investment and finance, Lucy has held positions at Woodford Investment Management, Goldman Sachs, and Jefferies, showcasing her expertise across both the corporate and financial sectors.
Leadership Comments
Dr. Frank Mathias, CEO of Oxford Biomedica, expressed his confidence in the new appointment:
“We are thrilled to have Lucy on board as our CFO. Her vast experience in finance, healthcare investment, and equity research will prove invaluable as we strengthen our international presence as a leading cell and gene therapy CDMO.”
Lucy Crabtree also shared her enthusiasm for the new role:
“I am excited to join Oxford Biomedica at such a pivotal time. The company’s growth strategy aligns perfectly with my own experiences, and I look forward to working alongside the leadership team to help deliver life-changing therapies to patients worldwide.”
Oxford Biomedica’s Vision
Oxford Biomedica has been at the forefront of cell and gene therapy for over 25 years. The company continues to partner with innovative pharmaceutical and biotech firms, offering expertise in viral vector development and manufacturing. Its operations span across the UK, France, and the US, making it a key player in the industry.
As Oxford Biomedica seeks to expand its global reach, Lucy’s appointment signals a commitment to financial growth and operational excellence. With her guidance, the company aims to continue enabling its partners to develop transformative therapies that impact patients’ lives.
Follow YourTechCFO for exclusive insights into her vision for growth and innovation!
